Kornimate/medical-research-clean huggingface dataset:
laparoscopic interval cytoreductive surgery in advance ovarian cancer

Conditions: Ovarian Neoplasms

Summary: this is a study that aims to demonstrate the non-inferiority of minimally invasive surgery versus open surgery, as an approach for patients with advanced ovarian cancer who received neoadjuvant chemotherapy, giving them the benefits of laparoscopic surgery. this way they can continue with their complementary treatment.


Eligibility criteria:
inclusion criteria: * diagnosis of epithelial ovarian cancer (all subtypes of epithelial ovarian cancer) in stage iii-iv * partial and complete response to treatment with qtna after 3-4 cycles, evaluated by pet-ct imaging study, patients that the functional unit decides to incorporate into the project. * ca 125 which will have to be less than 200 * ecog 0 to 2 without medical contraindication to perform surgery (≤ asa 2 or ≤ goldman 2). exclusion criteria: * partial response with persistence of ascites or pleural effusion. * with unresectability criteria (multiple intrahepatic liver metastases, retroperitoneal lymph node conglomerates \>2cm above the renal lymph nodes, metastatic disease above the diaphragm, multiple intestinal involvement and mesentery retraction).

Keywords: minimal invasive surgery interval debulking surgery advance ovarian cancer
an investigational immuno-therapy study of nivolumab compared to sorafenib as a first treatment in patients with advanced hepatocellular carcinoma

Conditions: Hepatocellular Carcinoma

Summary: the purpose of this study is to determine if nivolumab or sorafenib is more effective in the treatment of advanced hepatocellular carcinoma.


Eligibility criteria:
inclusion criteria: * histologically confirmed advanced hepatocellular carcinoma, not eligible for surgical and/or locoregional therapies; or progressive disease after surgical and /or locoregional therapies * locoregional therapy for hepatocellular carcinoma (hcc) must be completed at least 4 weeks prior to the baseline scan * child-pugh class a * eastern cooperative oncology group (ecog) performance status (ps) 0 or 1 exclusion criteria: * known fibrolamellar hcc, sarcomatoid hcc, or mixed cholangiocarcinoma and hcc * prior liver transplant * active, known, or suspected autoimmune disease other protocol-defined inclusion/exclusion criteria apply
stereotactic body radiotherapy (sbrt) post prostatectomy

Conditions: Prostate Cancer

Summary: this phase i study will assess the toxicity profile and efficacy of sbrt (stereotactic body radiotherapy) in patients with localized prostate cancer who are considered candidates for post-prostatectomy radiation.

radical prostatectomy is a common treatment for localized prostate cancer, patients with a detectable and/or rising psa after radical prostatectomy may be offered radiation. an increasing number of patients are being referred post-operatively for radiotherapy, which creates an added burden on radiotherapy departments. therefore, a strategy that could potentially decrease the number of radiotherapy fractions, yet maintain its efficacy, would be highly desirable for patient convenience, cost saving, and resource utilization as long as the toxicity profile is acceptable. this study will be conducted to asses the toxicity and efficacy of stereotactic body radiotherapy (sbrt) in post-prostatectomy patients.

Eligibility criteria:
inclusion criteria: * histologically confirmed diagnosis of adenocarcinoma of the prostate status post radical prostatectomy * completed written informed consent * able and willing to complete epic, porpus, and eq-5d questionnaires * a detectable psa ≤ 2.0 ng/ml * two consecutive rises in psa and final psa \> 0.1 ng/ml or three or more consecutive rises in psa exclusion criteria: * gross residual disease (per conventional imaging, i.e. ct and/or mri) * histological or radiological node +ve (n1) or distant metastases (m1) * prior pelvic radiotherapy * contraindications to radical pelvic radiotherapy (e.g. connective tissue disease or inflammatory bowel disease)

Keywords: sbrt ultrahypofractionated radiotherapy localized prostate cancer
a pharmacokinetic/pharmacodynamic study of oseltamivir in immunocompromised children with confirmed influenza infection

Conditions: Influenza

Summary: this open-label, randomized, adaptive, 2-arm, multicenter study will evaluate the pharmacokinetics and pharmacodynamics of oseltamivir (tamiflu) in immunocompromised children, less than (\<) 13 years of age, with confirmed influenza infection. participants will be randomized to receive either the standard dose or triple dose of oseltamivir orally daily for a minimum of 5 days and up to 20 days. infants \<1 year of age will be randomized to the standard dose arm only.


Eligibility criteria:
inclusion criteria: * male or female children, \<13 years of age * rapid influenza diagnostic test (ridt), polymerase chain reaction (pcr), or viral culture positive for influenza * immunocompromised * symptoms/signs suggestive of influenza like illness (ili) * less than or equal to (\</=) 96 hours between onset of ili and first dose of study drug exclusion criteria: * clinical evidence of severe hepatic impairment * infants with post-menstrual age (pma) \<36 weeks * clinical evidence of significant renal impairment * allergy to oseltamivir or excipients * hereditary fructose intolerance * received anti-viral treatment with activity against influenza (for example amantadine, rimantadine, oseltamivir, laninamivir, peramivir, zanamivir, and ribavirin) or probenecid medication within 2 weeks prior to randomization
prophylactic funnel mesh to prevent parastomal hernia in permanent end colostomy after abdomino-perineal resection

Conditions: Hernia; Colostomy Stoma

Summary: this retrospective study asses if a prophylactic, funnel-shaped, intraperitoneal mesh prevents parastomal hernia in patients undergoing abdominoperineal rectum resection with permanent end colostomy.


Eligibility criteria:
inclusion criteria: * elecitve abdominoperineal resection exclusion criteria: * rejection of a retrospective data analysis * age under 18 years * meshes other than the funnel-shaped mesh
palatability testing of a new paediatric formulation of valacyclovir

Conditions: Varicella Zoster Virus Infection; Herpes Simplex Virus Infection

Summary: palatability testing of a new paediatric formulation of valacyclovir in children 4-12 years of age and at least one of their parents. children will be included, who received (val)acyclovir prophylaxis in the past, or will probably need it in the future i.e. children with primary immune deficiency or cancer.


Eligibility criteria:
inclusion criteria: * subject is at least 4 years of age. * subject weighs at least 15kg. * subject is capable of performing the taste assessment, according to the investigator's judgement. * the child and parent(s) are willing to participate in the taste assessment. * signed informed consent by the legal guardian for participation of the child and if the parent also wants to participate: signed informed consent for their own participation, prior to start of the study. exclusion criteria: * documented history of sensitivity/idiosyncrasy to medicinal products or excipients. * presence of any condition that influences taste sensation (such as upper respiratory infection, febrile illness within 3 days before the first dose, mucositis or use of medication that influences taste perception, as described in the label information).

Keywords: prophylaxis herpes zoster herpes simplex valacyclovir palatability paediatric
peer support in alcohol dependence

Conditions: Alcohol Use Disorder

Summary: alcohol use disorder (aud) affects between 4% and 6% of french adults, and requires appropriate medical treatment. however, 20-40% of patients with aud are lost to follow-up at an early stage. consequently, it is important for addiction departments to implement and evaluate innovative tools and interventions, including the involvement of peer support, to help patients remain in care, and to assess whether peer support has a positive impact on their clinical outcome. addiction peer support specialists (apsss) are individuals who have personally experienced addiction, and who have decided to use their experience to assist other people going through a similar situation, after completing a specific official graduation. compared to other caregivers, apsss may induce in patients a sense of identification which could improve the patient motivation to engage and remain in care. this is the main hypothesis and the main scientific objective of the peersiad study, which will aim to confirm that accompanying patients with aud using apsss after alcohol detoxification, reduces the rate of lost-to-follow-up and improves the overall clinical outcome.


Eligibility criteria:
inclusion criteria: * aged ≥ 18 * socially insured * meeting dsm-5 criteria for alcohol use disorder (aud) * abstinent from alcohol and involved in supervised alcohol withdrawal for at least 5 days and no more than 21 days (outpatient or inpatient) * starting a post-detoxification outpatient program exclusion criteria: * other severe substance use disorder, i.e. dsm-5 criteria ≥ 6 (excluding tobacco) * patient under protective measure (safeguard measure, guardianship) or deprived of liberty or in ordered care and hospitalization measures without consent. * inability to communicate and express oneself orally in french, compromising the possibility of exchanges between the peer support and the patient. * psychiatric or cognitive comorbidities making inclusion impossible, at the investigator's discretion. * individual accompaniment by a peer support in the 15 days prior to inclusion.

Keywords: peer support addiction alcohol
the drug induced renal injury consortium

Conditions: Acute Kidney Injury; Adverse Drug Reaction; Acute Kidney Failure; Kidney Failure; Kidney Disease

Summary: some medications are known to cause kidney damage because the person is allergic to the medication while others cause direct damage to the kidney because they are toxic at certain concentrations. risk factors for developing kidney damage have been identified for some medications but not for all. patients who are exposed to these important medications and develop problems with their kidneys may have some genetic risk. the purpose of this study is to determine the genetic risk factors for drug induced kidney injury. a better understanding of the role of genetics for the development of kidney injury from medications will allow us to better select medications, improve effectiveness of treatment and minimize harm.


Eligibility criteria:
inclusion criteria: * patients age 2 years and older * exposure to a candidate drug for at least 24 hours (see above) * patients who have developed diri as defined by the primary criteria * written informed consent or assent and consent obtained * if patient lacks capacity to consent then surrogate consent will be obtained exclusion criteria: * patients with a history of or have a kidney transplant * patients with a history of or have a bone marrow transplant * patients with chronic kidney disease stage 5 (egfr \< 15 ml/min/1.73m2) * patients on 3 or more causal drugs * patients with no history or time course on drug exposure * patient who, in the opinion of the investigator, is not suitable to participate in the study. * unable to obtain written informed consent or assent * unable to obtain surrogate consent for patients who lack capacity

Keywords: acute kidney injury adverse drug reaction acute kidney failure kidney kidneys
a study to evaluate the efficacy and safety of abbv-8e12 in participants with early alzheimer's disease

Conditions: Alzheimer's Disease

Summary: this study seeks to evaluate the efficacy and safety of abbv-8e12 in participants with early alzheimer's disease (ad).


Eligibility criteria:
inclusion criteria: * subject who meets the national institute on aging and the alzheimer's association (nia-aa) clinical criteria for mild cognitive impairment or probable ad, and have: * clinical dementia rating (cdr)-global score of 0.5 * mini-mental state examination (mmse) score of 22 to 30, inclusive * repeatable battery for the assessment of neuropsychological status-delayed memory index (rbans - dmi) score of 85 or lower * subject has a positive amyloid positron emission tomography (pet) scan. * subject has a modified hachinski ischemic scale (mhis) score of ≤ 4. * the subject has an identified, reliable, study partner (e.g., family member). * if using medications to treat symptoms related to ad, doses must be stable for at least 12 weeks prior to randomization. exclusion criteria: * subject has any contraindications or inability to tolerate brain magnetic resonance imaging (mri), pet scans or lumbar puncture. * subject has evidence of any other clinically significant neurological disorder other than early ad. * in the opinion of the investigator, the subject has any clinically significant or uncontrolled medical or psychiatric illness, or has had an infection requiring medical intervention in the past 30 days. * subject has had a myocardial infarction, unstable angina, stroke, transient ischemic attack or required intervention for any of these conditions within 6 months of screening.

Keywords: early alzheimer's disease (ad) mild cognitive impairment (mci) mild alzheimer's disease (ad) tau early dementia tauopathies ad neurodegenerative diseases memory loss nervous system diseases
the role of cyberchondria severity in the relationship between hpv awareness and vaccination attitudes in adult women

Conditions: Human Papillomavirus Infection; HPV Vaccines; Cyberchondria; Awareness; Health Knowledge, Attitudes, Practice

Summary: human papillomavirus (hpv) is a prevalent sexually transmitted infection linked to nearly all cases (99%) of cervical cancer. prophylactic hpv vaccination is effective in preventing these cancers, complemented by hpv screening and treatment of precancerous lesions. the world health organization (who) aims to eliminate cervical cancer by 2030 through focused efforts on vaccination, diagnosis, and treatment. primary prevention strategies include reducing sexual risk factors and administering prophylactic vaccines. despite awareness of hpv testing, many women lack understanding of its importance and fail to follow through with screenings and necessary treatments. overall societal awareness of hpv remains inadequate. studies reveal disparities in hpv vaccine awareness: while 60.7% of women have heard of the vaccine, only 1% have received it. awareness varies widely across regions, with turkey reporting rates from 3.8% to 57%, and vaccine awareness ranging from 2.2% to 74.7% (özdemir et al., 2020). in the uk, concerns over potential negative results lead many women to defer hpv testing. health anxiety, defined as interpreting minor symptoms as serious health issues, drives individuals to seek excessive online health information, a phenomenon known as cyberchondria. studies link cyberchondria with heightened health anxiety, exacerbated by prolonged internet searches. barriers to hpv screening and vaccination include fear of side effects, lack of information, cost concerns, and anxiety over potential outcomes. while women testing positive for hpv show higher levels of cyberchondria, no direct correlation has been established between cyberchondria severity and hpv awareness or vaccination attitudes in adult women. this summary encapsulates the key findings and insights from the referenced studies on hpv, vaccination, and health anxiety.


Eligibility criteria:
inclusion criteria: * women aged 18-49 years old * at least elementary school education exclusion criteria: * individuals diagnosed with psychiatric disorders * women who are hpv (human papilloma virus) positive * any condition that would hinder communication (e.g., language barrier)
serologic response to pneumococcal vaccination among esophageal cancer patients with high grade lymphopenia after chemoradiation

Conditions: Pneumococcal Vaccine; Esophageal Cancer; Lymphopenia; Chemoradiation

Summary: to learn how radiation treatment may affect your responses to vaccines against pneumonia.

primary objectives - determine the impact of grade iv radiation-induced lymphopenia on serologic responses to pneumococcal vaccination. secondary objectives * determine the impact of chemoradiation on serologic responses to pneumococcal vaccination. * determine the impact of radiation modality on serologic responses to pneumococcal vaccination. * determine the impact of radiation modality on systemic immunity. * determine the incidence of pneumonia among patients treated with a pneumococcal vaccine. * determine the impact of radiation modality on pathologic response. * determine the impact of radiation modality on intratumoral immunity. * determine the relationship between changes in systemic and intratumoral immunity and clinical outcomes (i.e., incidence of pneumonia and pathologic response) * determine the impact of tumor histology on serologic responses to pneumococcal vaccination.

Eligibility criteria:
inclusion criteria: 1. group 1a a. participants currently receiving, planning to receive, or recently completed chemoradiation for esophageal cancer with protons. 2. group 1b a. participants currently receiving, planning to receive, or recently completed chemoradiation for esophageal cancer with intensity-modulated radiation therapy (imrt) 3. group 2a a. participants currently receiving, planning to receive, or recently completed definitive proton therapy for unresectable hepatocellular carcinoma. 4. group 2b a. participants currently receiving, planning to receive, or recently completed definitive imrt for unresectable hepatocellular carcinoma. 5. group 3 a. healthy age- and gender- matched individuals 6. all groups 1. participants of all genders, races and nationalities will be solicited. 2. age \>18 years 3. ability to understand and the willingness to sign a written informed consent document. exclusion criteria: * participants with compromised immunologic responses due to an uncontrolled intercurrent immunodeficiency (e.g., human immunodeficiency virus (hiv), x-linked agammaglobulinemia) or previous or current immune suppressive therapy a. human immunodeficiency virus (hiv)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial. * participants receiving intravenous immunoglobulin (ivig) during the study or in the three months prior to study enrollment. * participants with psychiatric illness/social situations that would limit compliance with study requirements. * participants with previous pneumococcal vaccination * participants with severe allergy to any of the vaccine components
a human trial to evaluate the efficacy and safety of fermented turmeric in subjects showing mild hepatic injury

Conditions: Mild Hepatic Injury

Summary: the investigators performed a double-blind parallel study in a group of showing mild hepatic injury subjects who were given fermented turmeric over a period of 12 weeks. the investigators measured liver function parameters , including alt(alanine transaminase), ast(aspartate transaminase), alp(alkaline phosphatase), γ-gt(gamma-glutamyl transferase), and serum bilirubin, and monitored their blood pressure.


Eligibility criteria:
inclusion criteria: * males and females 19-70 years old * mild hepatic injury as indicated by alt(alanine transaminase) level ≥ 40 * able to give informed consent exclusion criteria: * allergy or hypersensitivity to any of the ingredients in the test products * history of reaction to any of the experimental products or of gastrointestinal diseases such as crohn's disease or gastrointestinal surgery * carriers of viral hepatitis (type b and c) * history of underlying esophageal varices, hepatic encephalopathy, ascites(past 12 months) * participation in other clinical trials within the past 2 months * patients with acute hepatitis (type b and c) * history of underlying cirrhosis and liver cancer * history of underlying biliary diseases such as jaundice or gallstones * history of underlying kidney disease such as chronic renal failure or nephrotic syndrome * pregnant, planning to become pregnant, or breast-feeding * laboratory test, medical or psychological conditions deemed by the investigators to interfere with successful participation in the study
cpr training: video self-instruction kit or video-only

Conditions: Cardiovascular Risk Factors; Coronary Disease; Cardiac Arrest

Summary: prompt delivery of cardiopulmonary resuscitation (cpr) is a crucial determinant of survival for many victims of sudden cardiac arrest (sca), yet bystander cpr is provided in less than one third of witnessed sca events. a number of barriers to bystander cpr training have been identified including time and cost of the training course. since the large majority of arrest events occur in the home environment, studies have suggested that providing cpr training to family members of hospitalized cardiac patients may serve as a useful approach to address an environment in which bystander cpr is frequently not provided. utilizing an existing in-hospital program to train adult family members, the investigators will assess the skills of those who learn cpr through two different education methods (video-only and video self-instruction (vsi) kit).

the long term goal of the investigators work is to implement real world cpr training strategies that match training locales with at-risk populations, maximize resuscitation skill retention, and promote willingness to act. to accomplish this, the investigators will empower stakeholders at uphs and local area hospitals to develop local implementation approaches, using either volunteers or nursing staff as training proctors. these stakeholders will be studied as a research subset. the training proctors will train family members or friends of patients at risk for cardiac arrest using either a video-only method or video self-instruction (vsi) kit, and empower them with the lifesaving skill of cpr. the investigators will use the american heart association's cpr anytime vsi kit which comes equip with a dvd and inflatable manikin. for the group receiving the video-only method, the investigators will remove the inflatable manikin and train the subjects with the dvd. the investigators will randomize family members of high risk for ca to either the video-only or vsi kit method of training. the training proctors will be instructed to switch training methods every 6 months. the investigators will follow up with the study subjects and conduct cpr skills tests from 6 to 12 months from time of training to assess whether the subjects retained their skills or if they had an opportunity to use the skills that they learned. the investigators will also gather information on how the subjects would like to be encouraged to practice their skills. the investigators will send a reminder notification every two months following training, to encourage the subjects to refresh their training skills. at the follow-up skills test at 6 to 12 months, we will administer a survey to assess whether the prompting encouraged the subjects to practice their skills.

Eligibility criteria:
inclusion criteria: * family members of patients with known coronary disease or cardiovascular risk factors, such as history of diabetes and hypertension. exclusion criteria: * if someone is physically unable to undergo cpr training